Unfortunately, I'm not going to believe for one minute that this liver problem has suddenly shown its ugly face with Tysabri patients. The drug was in MS trials for more than two years. Same for Crohn's patients. During the trials these patients are monitored very closely. That's what they do in drug trials.

The responsibility of reporting what happened in the Tysabri trials lies with Biogen/Elan. I have never been a fan of those companies and have always questioned if we were being told everything about Tysabri. You start to hear information like this and it makes you wonder. I sure hope that MS patients are not again going to be subject to another possible therapy that may do more harm than good in the long run!

Harry